Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21797331 | 0.83 | CHRNB2 (0.42) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25858433 | 0.83 | CHRNB2 (0.42) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15778053 | 0.83 | CHRNB2 (0.42) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17212631 | 0.82 | APLNR (0.41) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15776462 | 0.81 | CHRNB2 (0.41) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16249319 | 0.81 | CHRNB2 (0.41) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14552089 | 0.80 | APLNR (0.42) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14031505 | 0.79 | CHRNB2 (0.39) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10084365 | 0.79 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14857774 | 0.79 | SMN1; SMN2 (0.42) | APLNRCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-112805267-B | Carboxamide and sulfonamide derivatives as TEAD modulators | 豪夫迈·罗氏有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| EP-3847154-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| US-20210188775-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | GENENTECH, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| WO-2018154466-A1 | DIHYDROQUINOLIZINONES AS ANTIVIRALS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-30 | — | — | WO | disclosed |
| US-9688669-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016001341-A1 | SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001341-A1 | SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011018495-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | APLNR 324/4885CHRNB2 1749/4885CHRNA4 3690/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | APLNR 1938/4885CHRNB2 267/4885CHRNA4 315/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | APLNR 4831/4885CHRNB2 4634/4885CHRNA4 3221/4885 |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | APLNR 774/4885CHRNB2 165/4885CHRNA4 70/4885 |
| US-20110212960-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER | BDNF, PSEN1, CHRNA5 | APLNR 2464/4885CHRNB2 55/4885CHRNA4 13/4885 |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | APLNR 1/4885CHRNB2 2126/4885CHRNA4 2888/4885 |
| US-20210188775-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | TEAD2, TEAD1, SULT2A1 | APLNR 4138/4885CHRNB2 4231/4885CHRNA4 3411/4885 |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | APLNR 4/4885CHRNB2 786/4885CHRNA4 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.